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ABSTRACT :  
Graft-versus-host disease assessment has been shown to be a challenge for healthcare professionals, 
leading to the development of the eGVHD App (www.uzleuven.be/egvhd). In this study, we formally 
evaluated the accuracy of using the App compared to traditional assessment methods to assess graft-
versus-host disease. Our national multicenter randomized controlled trial involved seven Belgian 
transplantation centers and 78 healthcare professionals selected using a two-stage convenience sampling 
approach between January and April 2017. Using a 1:1 randomization stratified by profession, healthcare 
professionals were assigned to use either the App (“APP”) or their usual graft-versus-host disease 
assessment aids (“No APP”) to assess the diagnosis and severity score of ten expert-validated clinical 
vignettes. Our main outcome measure was the difference in accuracy for graft-versus-host disease severity 
scoring between both groups. The odds of being correct were 6.14 (95% CI: 2.83-13.34) and 6.29 (95% 
CI: 4.32-9.15) times higher in favor of the “APP” group for diagnosis and scoring, respectively (p<0.001). 
App-assisted graft-versus-host disease severity scoring was significantly superior for both acute and 
chronic graft-versus-host disease, with an Odds Ratio of 17.89 and 4.34 respectively (p<0.001) and 
showed a significantly increased inter-observer agreement compared to standard practice. Despite a mean 
increase of 24 minutes (95% CI: 20.45-26.97) in time needed to score the whole graft-versus-host disease 
test package in the “APP” group (p<0.001), usability feedback was positive. The eGVHD App showed 
superior graft-versus-host disease assessment accuracy compared to standard practice and has the potential 
to improve the quality of outcome data registration in allogeneic stem cell transplantation.  
 
Abstract word count: 250  
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INTRODUCTION:  
Graft-versus-host Disease (GvHD) refers to the reaction of the transplanted immune system against the 
recipient’s tissues. This pleiotropic disease affects up to half of patients after allogeneic hematopoietic 
stem cell transplantation (HCT) and can damage any organ system to various degrees. It is by far the most 
debilitating complication of HCT, considering its major impact on morbidity and mortality1.  
 
Yet, because of the lack of widely available GvHD biomarkers, the assessment of the presence and 
severity of GvHD still relies mainly on the clinical evaluation of multiple organs according to a relatively 
complex algorithm. Moreover, the recommendations underlying this evaluation are plethoric and 
sometimes even contradictory, potentially leading to confusion in the HCT community1. In fact, it has 
been repeatedly shown that many HCT professionals have difficulties with the correct implementation of 
GvHD assessment, as demonstrated by a low observed accuracy in GvHD assessment2-5 and a slow uptake 
of the most up-to-date guidelines5-7. 
 
The eGVHD App is an electronic tool that we developed in collaboration with the EBMT Transplantation 
Complications Working Party and the National Institutes of Health (NIH) to assist healthcare 
professionals with their GvHD assessment4. This tool is a web application, available on mobile devices 
and desktop computers (see  www.uzleuven.be/egvhd for a complete list of the App’s characteristics). It 
allows intuitive and user-friendly access to the most recent international consensus guidelines and assists 
the user by automatically executing the required algorithm to calculate severity of GvHD, once the 
relevant clinical characteristics have been entered. 
  
Pilot testing was promising, suggesting improved GvHD assessment and good usability4, 5. Therefore, the 
primary aim of the present study was to compare the accuracy of the severity score of validated GvHD 
case-vignettes performed by healthcare professionals using the “eGVHD app” (“APP” group) with 
standard practice (“No APP” group). Secondary aims were to understand the characteristics that might 
affect the difference in accuracy between both groups and to compare the inter-observer variability in 
GvHD scoring results as well as the time needed to perform the GvHD evaluation of the full test package 
in both groups. We also assessed current practice patterns in GvHD assessment for all participants and 
post-test user satisfaction and experience in the “APP” group, to allow further improvement of the 
tool’s usability. To evaluate the generalizability of the tool, we tested the eGVHD App in a variety of 
settings and with a wide range of healthcare practitioners with different professional backgrounds. 
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We hypothesized that the eGVHD App would improve GvHD assessment by improving the accuracy of 
GvHD severity scoring by healthcare professionals and reducing inter-rater variability in scoring results, 
without increasing the time required to assess GvHD.  
  
METHODS:  
Design: 
This study used a hybrid design (Figure 1). The first part of the study consisted of a two-group 
multicenter randomized controlled trial assigning healthcare professionals 1:1 to an intervention group 
(“APP”) or a control group (“No APP”)  to evaluate the accuracy of GvHD assessment. The second part 
of the study was observational and described current practice patterns in GvHD assessment (“Survey 1”) 
and usability aspects linked to the use of the App (“Survey 2”).   
 
Sample and setting:  
All Belgian hospitals performing allogeneic HCT were invited to participate (Supplementary Table 1) to 
optimize sample size and generalizability. Centers were selected on their willingness to organize a GvHD 
workshop on their own premises within the allocated timeframe (January to April 2017). Healthcare 
professionals employed or studying at each participating hospital were recruited by convenience sampling. 
They were included provided they attended the workshop (see supplemental methods for workshop 
details) and could recall having performed at least one GvHD evaluation in the past 12 months. 
 
Data collection points, randomization procedure and blinding: see supplemental methods 
Outcome measures: 
The primary aim was to assess the difference in accuracy for GvHD severity scoring between the “APP” 
and “No APP” groups (see supplemental methods for the planned sub-analyses).  
 
Variables and measurements: 
Demographics and practice patterns in GvHD assessment:  
A self-report questionnaire (“Survey 1”) captured participant characteristics (Table 1) as well as 
practice pattern in GvHD assessment and pre-test technology access & acceptance data (Table 2) 
at baseline.   
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Accuracy of GvHD assessment:  
Participants were required to diagnose and score a package of ten randomly ordered GvHD 
clinical vignettes based on real-life clinical cases (see Supplemental Methods and 
Supplementary Table 2) according to the most up to date international guidelines1. Four aGvHD 
vignettes covered the two types of aGvHD diagnosis (‘classic aGvHD’ and ‘late aGvHD’, two 
vignettes each) and the four aGvHD overall severity stages (I-IV, one vignette per stage), 
according to the MAGIC criteria8. Six cGvHD vignettes covered the two cGvHD diagnoses 
(‘overlap cGvHD’ and ‘classic cGvHD’, two and four vignettes respectively) and the three 
severity grades of the NIH 2014 criteria9 (two vignettes per severity level, i.e. mild, moderate and 
severe). Answers were given by participants using a multiple choice form offering the following 
mutually exclusive options for diagnosis (‘classic aGvHD’, ‘late aGvHD’, ‘overlap cGvHD’ or 
‘classic cGvHD’)  and scoring (‘grade I’, ‘grade II’, ‘grade III’, ‘grade IV’, ‘Mild’, ‘Moderate’ or 
‘Severe’) respectively. 
 
The individual answer of each participant was compared to the gold standard (see Supplemental 
Methods) and scored as ‘correct’ (if the answer corresponded exactly to the expert evaluation) or 
‘incorrect’ (for any other answer, including missing answers) for diagnosis and severity scoring 
respectively (Supplementary Table 3). The total number of correctly evaluated vignettes for the 
whole GvHD test package was also recorded per individual (score ranging from 0 to 10 correct 
answers), for diagnosis and scoring separately. The time needed to complete the full GvHD test 
package was recorded for each participant individually by study staff. 
 
Control Group:  
Participants randomized to standard practice (“No APP” control group) were allowed to use any 
of their usual methods to assess GvHD: their own knowledge, ‘fast facts’ sheets, scoring sheets, 
standard operating procedures, copies of original guideline publications, or any other chosen 
resource.  
 
Intervention Group:  
Participants randomized to the “APP” group received the eGVHD App as a stand-alone GvHD 
assessment aid. 
 
Post-test user satisfaction and experience:  
 7 
 
Post-test user satisfaction and experience was recorded in “APP” users only by “Survey 2” using a 
semi-structured self-report questionnaire, and two validated instruments, the “perceived 
usefulness” subscale of the technology acceptance model (TAM) and the Post-Study System 
Usability Questionnaire (PSSUQ), as described previously4 (see supplemental methods and 
Supplementary Table 4 for details).  
 
Statistical analysis : see supplemental methods 
 
RESULTS  
Seven out of the eleven Belgian allogeneic HCT centers participated in the study (response rate 64%). 
They were essentially academic centers, covering together more than 80% of the Belgian allogenic 
transplantation activity (Supplementary Table 1).  
 
A total of 103 individuals participated in the workshops (Figure 2). Seventy-eight professionals met the 
inclusion criteria and were randomized. One participant dropped-out, due to a medical emergency in the 
clinic, hence data from 77 professionals were available for analysis: 37 in the “APP” Group and 40 in the 
“No APP” group. There was a median of 8 participants per center (range: 7-20, Supplementary Table 1). 
Professional characteristics were similar in both groups (Table 1). The majority of participants were 
medical doctors (75%), female (64%), and had a median age of 39 years (IQR: 20, range 22-62). 
Professionals reported a median experience in allogeneic HCT of 6 years (IQR: 11, range 0-32), and 
evaluated a median of one allogeneic HCT patient for GvHD per week  (IQR: 5, range 0-30). The majority 
of healthcare professionals reported having expertise in adult patient care. Self-reported proficiency in 
English was high with a median of 7 (IQR: 1; range: 2-10).  
 
Pre-test user current standard practice and technology access/acceptance 
The Glucksberg10 and the NIH 2014 criteria9 were the most frequently referenced GvHD assessment 
guidelines being used in clinical practice as reported by healthcare professionals (Table 2). Most 
professionals reported basing their usual GvHD evaluation on their own knowledge (n= 44, 57%), the NIH 
2014 GvHD evaluation sheet9 (n=17, 22%) and/or a self-designed scoring paper document (n= 16, 21%). 
The use of standard criteria to assess GvHD was reported as important (median score of 7 on a Likert 
scale of one to ten, IQR: 4, range 1-10), but performed with a relatively low level of confidence (median 
score of 5 on a Likert scale of one to ten, IQR : 4, range 1-9). The top four GvHD assessment problems 
spontaneously reported were: lack of knowledge or experience (n=23), time constraints (n= 16), lack of 
data in the medical files (n=7) and the complexity of the guidelines (n=5).  
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During the workshop, the “No APP” group planned to rely essentially on their own knowledge (n=24, 
62%), the NIH 2014 GvHD evaluation sheet9 (n=9, 23%), the NIH 2005 GvHD evaluation sheet11  (n=6, 
15%), a self-designed scoring document (n=6, 15%), and/or other methods (n=7, 18%) (Table 2). 
 
Accuracy of GvHD assessment 
The total number of correctly evaluated clinical vignettes was higher in the “APP” group compared to the 
“No APP” group (Table 3). More specifically, participants in the “APP” group had a median of 10 correct 
answers for diagnosis (IQR 1; range 5-10), compared to a median of 6.5 (IQR 3; range 2-9) in the “No 
APP” group for the whole GvHD test package (the maximum obtainable score was 10). For severity 
assessment, the “APP” group scored a median of 9 vignettes correctly (IQR 2; range 2-10) compared to a 
median of 4.5 (IQR 3; range 1-7) in the “No APP” group. Individual results for each vignette are shown in 
Supplementary Table 3. As a result, the odds of being correct were 6.14 (95% CI 2.83-13.34) and 6.29 
(95% CI 4.32-9.15) times higher in favor of the “APP” group for diagnosis and scoring respectively 
(p<0.001).  
 
All pre-specified sub-analyses were performed as planned. The GvHD assessment of the “APP” group 
remained superior for both acute and chronic GvHD separately (with a significantly stronger effect in 
acute GvHD (OR =17.89, 95% CI 8.47-37.79) compared to chronic GvHD (OR=4.34, 95% CI 2.79-6.74,  
p<0.001), and for all levels of severity scoring, except for aGvHD grade I. The effect of the App was more 
apparent for higher levels of severity (p=0.034) for both aGvHD and cGvHD. The strength of the effect 
did not significantly depend on center (Supplementary Figure 1) or professional background 
(Supplementary Figure 2). Similarly, neither the age of user (Supplementary Figure 3), the number of 
GvHD patients seen per week (Supplementary Figure 4) or self-reported comfort with using  GvHD 
guidelines (Supplementary Figure 5) seemed to mitigate the superior performance of the “APP” group.     
 
Agreement between participant results and the expert gold standard diagnosis and severity scoring are 
highlighted in the diagonal of Table 4, showing the superior performance of the “APP” group. For 
diagnosis, the most consistent errors of the “No APP” group were seen for case-vignettes relating to 
‘Overlap cGvHD’ and ‘Late aGvHD’, which both tended to be confused with ‘Classic cGvHD’. The 
highest discrepancies between the  “No APP” group and expert acute GvHD severity scoring results were 
seen in ‘grade II’ (which tended to be graded according to the cGvHD criteria)  and ‘grade IV’ aGvHD 
(which was essentially mistaken for ‘grade III’). Inconsistencies in chronic GvHD severity scoring were 
seen across all grades. The most frequent error in the “APP” group was a slight overestimation of the 
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cGvHD grade (overestimation n=34, 15%; underestimation n=20, 9%; missing/other n=4, 2%)  without 
any misclassification, whereas the “No APP” group tended to evaluate cGvHD severity erroneously 
according to the aGvHD criteria (n=62, 25%), without bias for severity (overestimation n=36, 14%, 
underestimation n=36, 15%, missing/other n=7, 3%).  
 
Consequently, inter-observer agreement of the severity score was higher in the “APP” group compared to 
standard practice: the probability that two HCT professionals agreed on the GvHD score equaled 0.73 and 
0.56 in the “App” and No APP” group, respectively. The chance-corrected agreement was significantly 
higher in the “APP” group (ΚBP= 0.46, 95% CI: 0.23-0.68) compared to the “No APP” group (ΚBP =0.12, 
95% CI: 0.03-0.21) (p=0.003).  
 
The time needed to complete the total test package was significantly higher in the “APP” group compared 
to the standard practice group, with a mean time of 48.84 minutes to complete all ten clinical vignettes in 
the “APP” group versus 25.27 minutes in the “No APP” group (p<0.001) (Table 3).  
 
Post-Test User satisfaction and experience 
No major technical issues were identified. Both “perceived usefulness” and “system usability” were 
considered to be good as shown in supplementary Table 4. Users reported being likely to use the 
eGVHD App in their daily practice and did not experience any issues with using the App in English. 
Spontaneously reported positive aspects of the eGVHD App were its clarity, ease of use and its systematic 
approach. Users suggested some potential improvements, such as decreasing its time-consuming 
components, reducing the number of evaluated items and clarifying some specific terms in more detail.  
 
DISCUSSION 
Several groups have recently advocated the use of electronic tools to improve GvHD assessment, albeit 
without providing formal proof of their efficacy1, 4, 12-14. In this rigorous multi-center randomized trial, we 
unequivocally demonstrate that the accuracy of GvHD assessment of clinical vignettes by healthcare 
professionals is significantly higher when using the eGVHD App compared to standard practice. This 
effect was seen for both acute and chronic GvHD, across all severity levels (except for aGvHD grade I), 
all degrees of experience and professional backgrounds, without any evidence for center effect.  
 
In this study, participants in the control group were allowed to use any method of their choice to support 
their GvHD assessment, except for using the eGVHD App. Yet GvHD assessment results in the APP 
group, were strikingly better. We believe that the superior performance of the App users could be due to a 
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number of factors. First, App users were provided with the most up-to-date guidelines1, without having to 
look them up actively. Second, similar to using comprehensive paper data collection forms, they were 
encouraged to work in a systematic fashion: they had to evaluate every possible aspect of acute or chronic 
GvHD  (to avoid overlooking less intuitive aspects of the disease) in order to select the appropriate scoring 
system and come to the correct severity evaluation result. Finally, the digital interface also offered users a 
number of advantages such as the presence of pictures and definitions to support recognition of GvHD-
related features, the use ‘skip-logic’ principles (which allows healthcare professionals to avoid wasting 
time on filling in information with no direct impact on diagnosis or severity scoring), the automatic 
computation of the resulting score and the option of generating a report. 
 
We have to acknowledge that this superior performance was achieved at the cost of a significant increase 
in time needed to score clinical vignettes, with an excess of about 24 minutes to score the ten clinical 
vignettes compared to using standard methods. This was partially due to the fact that “APP” users needed 
to get used to a tool they had never worked with before. Yet, healthcare professionals remained open to 
the use of eHealth technology, both before and after actually using the App. The eGVHD App showed 
excellent usability, as no major technical issues were noted and user feedback was widely positive, 
suggesting a potential for optimal dissemination and uptake in the HCT community. Furthermore, in the 
event where the App-computed scores would be directly transferred into the electronic medical record 
(eHR), the additional time spent inputting data into the App would be rewarded with potentially less time 
charting and more accurate data collection. However, this integration also supposes a number of basic pre-
requisites, which still need to be developed: data cleaning methods to ensure the quality of data entry, the 
possibility of cross-talk between the eGVHD App and the different eHR systems, the reliability, privacy 
and safety of data transfer and the option of identifying the individual who performed the data input. 
 
Consistent with prior literature, our practice pattern survey showed the lack of consensus in the HCT 
community as to which set of international recommendations should be used to assess GvHD, and 
confirmed numerous barriers to their successful dissemination and implementation5-7. The lack of 
consensus and knowledge of the most recent guidelines was maybe due to the low number of HCT 
patients seen per week and probably partly explains the lower results obtained by the group using 
traditional methods. However, this also highlights the need to standardize GvHD evaluation within the 
HCT community, as recently advocated by a panel of GvHD experts1. It is precisely in this context of lack 
of confidence and expertise in GvHD assessment that e-Tools, such as the eGVHD App, have the 
potential to increase the quality of data collection by allowing for an easy, reliable, user-friendly and 
intuitive access to the most up-to-date guidelines to any healthcare professional. Regrettably, we were 
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unable to test the effect of the App specifically in smaller Belgian centers, as they declined participation to  
this study. We are therefore unable to speculate on the generalizability of this tool in centers with lower 
transplantation volumes.  
 
The limited number of vignettes also makes it challenging to make any meaningful conclusions on 
specific subgroups or at the organ level. The significant difference in improved accuracy for aGvHD 
scoring compared to cGvHD scoring is probably simply due to the fact that each of the four aGvHD 
severity levels was evaluated by a single clinical vignette (instead of two per severity level for cGvHD). 
For instance, in the ‘late acute GvHD grade II’ clinical vignette, the largely incorrect final severity 
evaluation reported by the “No APP” group was partially conditioned by the fact that the distinction 
between acute and chronic GvHD had not been made in the first place. Moreover, the MAGIC criteria 
were not the standard reference for aGvHD for the majority of the participants, which could explain the 
exceptionally poor results for the grade IV aGvHD vignette when evaluated by the “No APP” group.  
 
The limited number of observations also restrict our  ability to make any conclusions on the potential 
impact of using the App in the clinical setting to decide upon starting treatment, as the threshold to start 
therapy is linked to much broader categories than the ones described above (typically, any grade above or 
equal to ‘aGvHD grade II’ or ‘cGvHD moderate’ would qualify for treatment, depending on the general 
health status of the patient15-17). Treatment adaptions rely also on specify response criteria18, 19, which were 
not investigated in this project.  Future work therefore needs to evaluate the use and impact of the eGVHD 
App in clinical encounters. This will also allow the evaluation of the App in situations where the patient 
does not present with GvHD, considering that the test package evaluated here only evaluated the tool in 
the context of GvHD-afflicted patients, precluding the evaluation of detection measures such as predictive 
values, sensitivity and specificity.  
 
Further limitations of this study are the lack of repeated measures and the unnatural setting of clinical 
vignettes, which are unable to perfectly mirror the wide variations in GvHD presentation in real life and 
their relative incidence. This particular experimental design was chosen to simplify logistics, optimize 
healthcare professional participation, avoid patient bother and keep respondent burden to a minimum. It 
also allowed for multiple experts to validate the GvHD assessment. Such an expert consensus is rarely 
obtained in clinical practice, but was considered to be the best gold standard available to date to serve as 
reference for the accurate scoring during GvHD assessment.     
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So, it remains to be determined whether the App will also improve accuracy when being used in real life 
circumstances. Yet, even in this artificial setting, the low spontaneous GvHD scoring accuracy obtained in 
this evaluation with traditional methods (obtaining a median of 4.5 correctly scored vignettes out of a 
maximum of ten) is in line with the results of a previous validation study done in a more real-world 
setting. This study included actual patient examinations and showed that only 50% to 75% of freshly 
trained clinicians actually agreed with experts on the overall severity score of the evaluated chronic GvHD 
patients 6. Mitchell and colleagues concluded that a single training session was insufficient to achieve 
consistently acceptable inter-rater agreement between novice healthcare practitioners and GvHD experts. 
Clinical training in GvHD physical exams may thus be necessarily to achieve reproducible severity 
assessment with high inter-rater reliability in practice. By ensuring the systematic assessment of all organs 
potentially affected by GvHD, the App can also serve as a training tool, aiming at making healthcare 
professionals ultimately independent of technological assistance. 
 
The eGVHD App is currently limited to a calculator function that evaluates the patient at a single point in 
time. Expanding on our promising accuracy results and user-feedback, future plans include the 
development of a module to perform longitudinal patient evaluations (with an integrated disease response 
evaluation according to international criteria18, 19) and a module to capture patient-reported GvHD 
evaluation based on the Lee symptom scale20. These added functionalities will dramatically increase the 
clinical usefulness of the tool in following patients over time. 
 
However, a challenging issue with eHealth tools is how to approach their constant and rapid change over 
time. This evolution is driven by evolving clinical practices, user feedback and updates in computer 
programs and/or operating systems. The results reported in this study, for instance, have been obtained 
with a version of the eGVHD app, which has already become obsolete, as a new version (using additional 
skip-logic features)  has been developed to address the rightful criticism about the time-consuming aspect 
of use. The constant evolution of the virtual world is a challenge in the current context of European 
regulation (EU Directive 93/42/EEC  MEDDEV 2. 4/1 Rev. 9 June 2010), which requires eHealth 
applications to be formally validated by a tedious quality insurance process at every adaptation of the tool. 
This is not practically feasible in real life and probably more often than not, unnecessary. Health 
regulations agencies will need to adjust their requirements in the near future, to allow for this dynamic 
progress of the cyber world, even for healthcare applications. This is, in fact, probably one of the most 
challenging aspects of integrating eTools in modern models of care21.  
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Compared to other smaller scaled initiatives, which have shown successful implementation of eHealth 
technologies in local electronic medical record systems 14 or specific research programs 12, 13 to assess 
GvHD, the eGVHD App is now ubiquitously available (www.uzleuven.be/egvhd) for all healthcare 
professionals who wish to get bedside user-friendly assistance in their GvHD assessment, to improve their 
expertise and/or the uniformity of their GvHD data collection, both in daily practice and in clinical trials. 
Further validation regarding its usefulness and scalability will therefore be able to rely on the analysis of 
the real-life data generated by downloads and feedback from users, based on implementation research 
principles. If results are convincing, next steps could include the direct integration of eGVHD App-
generated data in larger registry databases and electronic medical record systems to circumvent the need to 
produce separate reports and repeat data entry. Such developments will require further reflections on how 
to achieve optimal control of the quality of the entered data and guarantee its privacy protection according 
to local laws.  
 
In conclusion, the eGVHD App shows superior accuracy for the GvHD assessment of clinical vignettes 
compared to usual care and has therefore the potential to improve the quality of GvHD data in clinical 
research and practice. In the era of electronic medical files, ‘big data’ and increased connectivity, e-Tools 
are likely to become widespread in our daily practice and could even gradually turn the patient-himself 
into his own data-manager and most involved advocate.  Only time and continuous research will tell 
whether such tools can be effectively used in clinical practice and whether healthcare professionals are 
ready to accept IT assistance to solve some of their practical issues. 
 
Article word count:  3941 
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Tables 
Table 1:  Characteristics of workshop participants 
 
Professional Background 
Whole group 
 (n= 77) 
APP 
(n=37) 
No APP 
(n=40) 
Senior physicians - n (%) 37 (48%) 18 (49%) 19 (48%) 
Junior physicians - n (%) 21 (27%) 10 (27%) 11 (27%) 
Data managers - n (%) 15 (19%) 7 (19%) 8 (20%) 
Others - n (%) 4 (5%) 2 (5%)* 2 (5%)** 
Demographics    
Gender - n (%) 28 males (36%) 
49 females (64%) 
13 males (35%) 
24 females (65%) 
15 males (37%) 
25 females (62%) 
Median age (years) 
 
≤30 – n (%) 
31-40 – n (%) 
41-50 – n (%) 
≥51– n (%) 
39 
(IQR: 20; range: 22-62) 
24 (31%) 
18 (23%) 
18 (23%) 
17 (22%) 
40 
(IQR: 18; range: 24-62) 
11 (30%) 
9 (24%) 
11 (30%) 
6 (16%) 
36.5 
(IQR: 22; range: 22-59) 
13 (33%) 
9 (23%) 
7 (18%) 
11 (28%) 
Median experience in hematology 
(years) 
7.5 
(IQR: 19; range: 0-34)$ 
7 
(IQR: 14; range: 0-34) 
8 
(IQR: 21; range: 0-32)$ 
Median experience in HCT (years) 6 
(IQR: 11; range: 0-32)$ 
6 
(IQR: 12; range: 0-32) 
6 
(IQR: 11; range: 0-32)$ 
Median number of HCT patients 
evaluated for GvHD per week  
very low (<1) - n (%)  
  low (1-6) - n (%)  
moderate (7-15) - n (%)  
high (>15) - n (%)  
1 
(IQR: 5; range: 0-30)$$  
25 (33%) 
38 (51%) 
6 (8%) 
6 (8%) 
1 
(IQR: 5; range: 0-30) 
13 (35%) 
17 (46%) 
4 (11%) 
3 (8%) 
1 
(IQR: 5; range: 0-25)$$ 
12 (32%) 
21 (55%) 
2 (5%) 
3 (8%) 
Area of expertise  
Adults only - n (%) 
Children only – n (%) 
Both adults and children – n (%) 
 
67 (87%) 
2 (2%) 
7 (9%)$ 
 
32 (86%) 
2 (5%) 
3 (8%) 
 
35 adults only (87%) 
0 children only (0%) 
4 both (10%)$ 
Median proficiency in English (1-10) 7 (IQR: 1; range: 2-10)$$ 7.5 (IQR: 2; range: 2-10)$ 7 (IQR: 1; range: 3-10)$ 
 18 
 
LEGEND 
CI: confidence interval; IQR: inter quartile range; HCT: hematopoietic stem cell transplantation; OR: 
Odds ratio; $ = one respondent missing; * two nurses;  ** one nurse and one medical student 
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Table 2: Survey 1 Results : Pre-test Practice Patterns, Technology Access and Technology 
Acceptance Data  
 
Practice Patterns in 
GvHD assessment 
Whole group  
(n= 77) 
APP  
(n=37) 
No APP  
(n=40) 
Most often used 
International Guidelines* 
- n (%) 
   
Glucksberg criteria 24 (31%) 12 (32%) 12 (30%) 
IBMTR Criteria 5 (7%) 2 (5%) 3 (8%) 
MAGIC criteria 13 (17%) 4 (11%) 9 (23%) 
Seattle Criteria 13 (17%) 6 (16%) 7 (18%) 
NIH 2005 Criteria 14 (18%) 5 (14%) 9 (23%) 
NIH 2014 Criteria 27 (35%) 17 (46%) 10 (26%) 
Other / Does not know 11 (14%) 7 (19%) 4 (10%) 
Reported level of ...  
(Likert scale 1 (lowest)-
10 (highest)) 
   
Median importance of 
the guidelines 
7  
(IQR 4 - range: 1-10)$$$$$$ 
6  
(IQR 4 - range: 1-10)$$$ 
7  
(IQR 5 - range: 1-10)$$$ 
Median comfort in 
applying the guidelines 
Low (≤ 4) – n (%) 
Moderate (5-7) – n (%) 
High (≥ 8) – n (%) 
5  
(IQR 3 - range: 1-9)$$$ 
31 (42%) 
35 (47%) 
8 (11%) 
5  
(IQR 4 - range: 1-9)$$ 
17 (49%) 
14 (40%) 
4 (11%) 
5  
(IQR 3 - range: 1-9)$ 
14 (35%) 
21 (54%) 
4 (10%) 
In my daily practice, my 
GvHD assessment relies 
on…* - n (%) 
   
Own knowledge 44 (57%) 18 (50%) 26 (65%) 
A self-designed paper 
form 
16 (21%) 7 (19%) 9 (23%) 
A self-designed electronic 
file 
5 (7%) 2 (5%) 3 (8%) 
 20 
 
The official NIH 2005 
paper form 
8 (10%) 3 (8%) 5 (13%) 
The official NIH 2014 
paper form 
17 (22%) 10 (27%) 7 (18%) 
Other 14 (18%) 8 (22%) 6 (15%) 
Not answered 2 (3%) 1 (3%) 1 (3%) 
During the study, my 
GvHD assessment will 
rely on…* 
 - n (%) 
   
Own knowledge NA NA 24 (62%) 
A self-designed paper 
form 
NA NA 6 (15%) 
The official NIH 2005 
paper form 
NA NA 6 (15%) 
The official NIH 2014 
paper form 
NA NA 9 (23%) 
Other NA NA 7 (18%) 
Not answered NA NA 1 (3%) 
Technology Access     
To support my daily 
practice, I have access 
to…*   
- n (%) 
   
A desktop computer with 
no internet connection 
7 (9%) 3 (8%) 4 (10%) 
A desktop computer 
with an internet 
connection 
70 (91%) 34 (92%) 36 (90%) 
A portable device 33 (43%) 17 (46%) 16 (40%) 
A WIFI connection 31 (40%) 13 (35%) 18 (45%) 
An electronic patient 
medical file 
48 (62%) 24 (65%) 24 (60%) 
 21 
 
Other   2 (3%) 0 (0%) 2 (5%) 
Not answered 3 (4%) 1 (3%) 2 (5%) 
Predicted use      
Localization of use*   
- n (%) 
   
Bedside 23 (30%) 12 (32%) 11 (28%) 
Deskside 57 (74%) 27 (73%) 30 (75%) 
Unlikely to use 2 (3%) 2 (5%) 0 (0%) 
Other   1 (1%) 0 1 (3%) 
Not answered 2 (3%) 0 2 (5%) 
Type of device used*   
- n (%) 
   
Cellphone 43 (56%) 25 (68%) 18 (45%) 
Tablet 5 (7%) 2 (5%) 3 (8%) 
Laptop 6 (8%) 3 (8%) 3 (8%) 
Desktop 32 (42%) 10 (27%) 22 (55%) 
Other   0 (0%) 1 (0%) 0 (0%) 
Not answered 2 (3%) 0 2 (5%) 
Language    
Median importance of the 
availability of the app in 
my native language  
(Likert scale 1 (lowest)-
10 (highest)) 
4  
(IQR 5; range: 1-10)$$ 
4  
(IQR 6; range: 1-10) 
4  
(IQR 5; range: 1-10)$$ 
Technology Acceptance 
Data 
   
Median reported level of 
likelihood of using the 
app  (Likert scale 1 
(lowest)-10 (highest)) 
8  
(IQR 3; range: 1-10)$$$$$$ 
7.5  
(IQR 3; range: 1-10)$ 
8  
(IQR 4; range: 1-10)$$$$ 
 
  
 22 
 
 
LEGEND 
CI: confidence interval; IQR: inter quartile range; NA: not applicable; OR: Odds ratio; * several answers 
were possible; $ = one participant missing 
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Table 3: GvHD Assessment Package Accuracy and Timing Results 
Results for the complete GvHD test 
package (median) 
APP (n=37) No APP (n=40) 
Correctly Diagnosed Vignettes            
(maximum 10 correct answers) 
10 
(IQR 1; range 5-10) 
6.5 
(IQR 3; range 2-9) 
Correctly Scored Vignettes                 
(maximum 10 correct answers) 
9 
(IQR 2; range 2-10) 
4.5 
(IQR 3; range 1-7) 
Results for acute and chronic GvHD 
(median) 
APP (n=37) No APP (n=40) 
 
Correctly Scored acute GvHD Vignettes  
(maximum 4 correct answers) 
4 
(IQR 0; range 2-4) 
2 
(IQR 2; range 0-4) 
Correctly Scored chronic GvHD Vignettes 
(maximum 6 correct answers) 
5 
(IQR 1; range 0-6) 
3 
(IQR 2.25; range 0-5) 
Time needed to complete the  whole GvHD 
test package 
APP (n=37) No APP (n=40) 
 
Mean time to complete all Vignettes 
(minutes) 
48.84 
(Std dev: 10.3; range 31-67) 
25.27 
(Std dev: 9.76; range 9-54) 
 
LEGEND 
CI: confidence interval; IQR: inter quartile range; Std dev: standard deviation 
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Table 4: Detailed Results of Participants for GvHD vignettes Compared to the Expert Gold 
Standard       
  Results from the "App" group given by 37 participants - n (%) 
Expert Gold Standard 
Diagnosis 
Classic 
Acute 
Late   
Acute 
Classic 
Chronic 
Overlap 
Chronic 
Missing Other Total 
Classic acute GVHD °° 67 
(91%) 
4 
(5%) 
0 
(0%) 
2 
(3%) 
1 
(1%) 
0 
(0%) 
74 
(20%) 
Late acute GVHD °° 5 
(7%) 
65 
(88%) 
1 
(1%) 
3 
(4%) 
0 
(0%) 
0 
(0%) 
74 
(20%) 
Classic Chronic GVHD °°°° 3 
(2%) 
0 
(0%) 
140 
(95%) 
3 
(2%) 
2 
(1%) 
0 
(0%) 
148 
(40%) 
Overlap Chronic GVHD °° 0 
(0%) 
0 
(0%) 
4 
(5%) 
69 
(93%) 
0 
(0%) 
1 
(1%) 
74 
(20%) 
Total 75 
(20%) 
69 
(18%) 
145 
(39%) 
77 
(21%) 
3 
(1%) 
1 
(0%) 
370 
(100%) 
  Results from the "No App" group given by 40 participants - n (%) 
Expert Gold Standard 
Diagnosis 
Classic 
Acute 
Late   
Acute 
Classic 
Chronic 
Overlap 
Chronic 
Missing Other Total 
Classic acute GVHD °° 76 
(95%) 
0 
(0%) 
1 
(1%) 
2 
(3%) 
1 
(1%) 
0 
(0%) 
80 
(20%) 
Late acute GVHD °° 7 
(9%) 
52  
(65%) 
16 
(20%) 
5 
(6%) 
0 
(0%) 
0 
(0%) 
80 
(20%) 
Classic Chronic GVHD °°°° 18 
(11%) 
9  
(6%) 
110 
(69%) 
23 
(14%) 
0 
(0%) 
0 
(0%) 
160 
(20%) 
Overlap Chronic GVHD °° 3 
(4%) 
10 
(13%) 
51 
(64%) 
16 
(20%) 
0 
(0%) 
0 
(0%) 
80 
(20%) 
Total 104 
(26%) 
71 
(18%) 
178 
(44%) 
46 
(11%) 
1 
(0%) 
0 
(0%) 
400 
(100%) 
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  Results from the "App" group given by 37 participants - n (%) 
Expert Gold Standard 
Severity Scoring 
Grade 
I 
Grade 
II 
Grade 
III 
Grade 
IV 
Mild Moderate Severe Missing Other Total 
Grade I ° 33 
(89%) 
1 
(3%) 
0 (0%) 0 (0%) 2 (5%) 1 
(3%) 
0 (0%) 0 
(0%) 
0 (0%) 37 
(10%) 
Grade II ° 0 (0%) 37 
(100%) 
0 (0%) 0 (0%) 0 (0%) 0 
(0%) 
0 (0%) 0 
(0%) 
0 (0%) 37 
(10%) 
Grade III ° 0 (0%) 0 
(0%) 
35 
(95%) 
0 (0%) 0 (0%) 0 
(0%) 
2 (5%) 0 
(0%) 
0 (0%) 37 
(10%) 
Grade IV  ° 0 (0%) 1 
(3%) 
3 (8%) 33 
(89%) 
0 (0%) 0 
(0%) 
0 (0%) 0 
(0%) 
0 (0%) 37 
(10%) 
Mild °° 0 (0%) 0 
(0%) 
0 (0%) 0 (0%) 49 
(66%) 
22 
(30%) 
1 (1%) 1 
(1%) 
1 (1%) 74 
(20%) 
Moderate °° 0 (0%) 0 
(0%) 
0 (0%) 0 (0%) 0 (0%) 61 
(82%) 
11 
(15%) 
1 
(1%) 
1 (1%) 74 
(20%) 
Severe °° 0 (0%) 0 
(0%) 
0 (0%) 0 (0%) 2 (3%) 18 
(24%) 
54 
(73%) 
0 
(0%) 
0 (0%) 74 
(20%) 
Total 33 
(9%) 
39 
(10%) 
38 
(10%) 
33 
(9%) 
53 
(14%) 
102 
(27%) 
68 
(18%) 
2 
(0%) 
2 
(0%) 
370 
(100%) 
  Results from the "No App" group given by 40 participants - n (%) 
Expert Gold Standard 
Severity Scoring 
Grade 
I 
Grade 
II 
Grade 
III 
Grade 
IV 
Mild Moderate Severe Missing Other Total 
Grade I ° 29 
(73%) 
4 (10%) 0 (0%) 0 (0%) 4 
(10%) 
1 
(3%) 
0 (0%) 0 
(0%) 
2 (5%) 40 
(10%) 
Grade II ° 3 (8%) 11 
(28%) 
4 
(10%) 
1 (3%) 3 (8%) 13 
(33%) 
4 (10%) 1 
(3%) 
0 (0%) 40 
(10%) 
Grade III ° 0 (0%) 0 
(0%) 
27 
(68%) 
9 
(23%) 
0 (0%) 1 
(3%) 
1 (3%) 0 
(0%) 
2 (5%) 40 
(10%) 
Grade IV  ° 1 (3%) 8 (20%) 19 
(48%) 
7 
(28%) 
1 (3%) 2 
(5%) 
0 (0%) 0 
(0%) 
2 (5%) 40 
(10%) 
Mild °° 13 
(16%) 
12 
(15%) 
0 (0%) 0  
(0%) 
32 
(40%) 
19 
(24%) 
2 (1%) 1 
(1%) 
1 (1%) 80 
(20%) 
Moderate °° 5 (6%) 8 (10%) 4 (5%) 0  
(0%) 
5 (6%) 40 
(50%) 
15 
(19%) 
0 
(0%) 
3 (4%) 80 
(20%) 
Severe °° 1 (1%) 9 (11%) 9 
(11%) 
1  
(1%) 
8 
(10%) 
23 
(29%) 
27 
(34%) 
0 
(0%) 
2 (3%) 80 
(20%) 
Total 52 
(13%) 
52 
(13%) 
63 
(16%) 
18 
(4.5%) 
53 
(13%) 
99 
(25%) 
49 
(12) 
2 
(0%) 
12 
(3%) 
400 
(100%) 
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LEGEND         
NA = Not Applicable; vs. = versus; ° one clinical vignette; "Missing" corresponds to a lack of answer; 
"Other" corresponds to any answer not matching the proposed choices; The highlighted diagonal 
corresponds to the perfect agreement between participants and expert results.  
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Figures 
Fig 1 – Study Design 
Legend: APP: eGVHD App; GvHD: graft versus host disease 
 
Fig 2 – CONSORT flow diagram  
Legend: APP: eGVHD App; HCP: healthcare professional; HCT: hematopoietic stem cell transplantation 
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Supplemental methods 
Sample and setting –  Workshop description 
The workshop lasted 90 to 120 minutes. It consisted of an introduction to the eGVHD App project, a short 
tutorial to train the “APP” group in the basic functionalities of the eGVHD App and the completion of a 
demographics, practice patterns and technology acceptance survey (“Survey 1”)  by all participants. Both 
groups then received the GvHD test package and recorded their answers individually. This was followed 
by a usability survey (“Survey 2”) restricted to the “APP” group. The workshop concluded with a 
discussion of the correct answers of the test package and a summary of the most current recommendations 
for GvHD assessment. 
 
Data collection points, randomization procedure and blinding  
All data collection was performed during the workshop using pen and paper. Allocation to the intervention 
arm (“APP” group) was random and stratified. More specifically, randomization was done at the arrival of 
study participants based on pre-formatted randomization sheets (www.randomization.com) and order of 
arrival. We used randomly permuted blocks, with block sizes of 2, to compensate for the low number of 
participants per center. Stratification was based on professional background: (1) senior physicians (board 
certified hematologists), (2) junior physicians (medical doctors training in internal medicine or 
hematology), (3) data managers or research nurses specialized in HCT data entry or (4) other (e.g. medical 
students or nurses with no specific GvHD evaluation expertise). Blinding was not feasible due to the 
nature of the intervention. 
 
Outcome measures – Planned sub-analyses 
We planned the following sub-analyses: (1) to compare the difference in diagnosis accuracy between both 
groups, (2) to test for the App-effect on the accuracy of the severity scoring conditional on a GvHD 
diagnosis being acute (aGvHD) and chronic (cGvHD), (3) to verify whether the effect of the App 
depended on the type of GvHD, the severity of GvHD, professional background or center, (4)  to compare 
the inter-rater reliability and  (5)  to compare the time needed to complete the full test package between 
both groups. 
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Variables and measurements 
Gold Standard 
Prior to this study, four GvHD experts (SZP, DW, AI and SJL) determined the correct diagnosis 
and severity score of each vignette, based on the  MAGIC criteria1 for acute GvHD and the NIH 
2014 guidelines2 for chronic GvHD by evaluating the ten clinical vignettes independently and 
returning their GvHD assessment separately to the principal investigator. The ‘gold standard’ for 
diagnosis and severity scoring corresponded to the answer given by at least three of the four 
experts. When an expert disagreed with the consensus of the other three experts, this expert was 
contacted separately to confirm that he/she agreed with the ‘gold standard’ answer given by the 
rest of the group.  
 
Experts were healthcare professionals active in the field of allogeneic HCT, co-authors of at least 
one publication in the field of clinical GvHD and active members of an international GvHD 
consortium or working group.  
 
Post-test user satisfaction and experience  
Briefly, the TAM consists of six statements, referring to the extent to which the user believes the 
technology will improve his work performance. Statements are rated on a 7-point Likert-like scale 
(1= ‘extremely unlikely’ to 7= ‘extremely likely’). A median score is calculated for each item 
separately, with higher scores reflecting higher perceived usefulness. The PSSUQ is a 19-item 
questionnaire using 7-point Likert-like scales (1= ‘strongly agree’ to 7= ‘strongly disagree’), with 
three subscales reflecting system usefulness (items 1-8), information quality (items 9-15) and 
interface quality (items 16-18), respectively. PSSUQ scores are presented as median total and 
subscale scores, with lower scores reflecting higher user satisfaction. 
 
Statistical analysis 
Results were analyzed with IBM SPSS statistics version 24 and R version 3.3.3 according to the ‘intention 
to treat’ principle. Missing results were reported as such. Descriptive results were reported using a 
measure of central tendency and a measure of dispersion, as appropriate. The probability of a correct 
answer was compared between both groups using a mixed effects logistic regression model, for diagnosis 
and severity score separately. The model contained fixed effects of group (“App” versus “No App”) and 
professional background (the stratification variable in the randomization) and random effects of center and 
workshop participant. These random effects were included to handle the correlation between the workshop 
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participants belonging to the same center, and between the ten answers given by the same workshop 
participant, respectively. Odds ratio’s and 95% confidence intervals (CI) for the effect of group were 
reported. To verify whether the effect of the App depended on the type of the GvHD, the severity of the 
GvHD, professional background or center, interaction terms were added in separate models. Inter-
observer agreement of the severity was evaluated by using the Brennan-Prediger’s kappa coefficient (ΚBP) 
which ranges between zero (no agreement) and one (perfect agreement). This coefficient evaluates the 
raters’ agreement for nominal scales with more than two categories and takes into account the fact that 
agreement could have occurred by chance.  This version of the kappa is reported instead of the classical 
Fleiss-Cohen kappa, since the latter is not appropriate for comparisons of conditions having a difference in 
distribution3. Kappa’s are compared between both groups using an approach presented by Gwet and 
colleagues4. The time needed to score the vignettes was compared between both groups using a linear 
mixed model, with the same fixed and random effects as in the aforementioned logistic regression model. 
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Supplemental Tables 
Supplementary Table 1:  
Characteristics of Centers Performing Allogeneic HCT in Belgium and Participating in the Study  
Center Academic 
Center 
total 
HCT 
per 
year 
1st 
alloHCT 
per year 
% 
activity  
in 
Belgium 
total 
number of 
participants 
Senior 
MD 
Junior 
MD 
Data 
managers 
Other 
1 yes 130 76  
 
 
82% 
20 8 8 4 0 
2 yes 95 57 13 5 4 3 1 
3 no 87 33 8 3 2 1 2 
4 yes 74 34 7 4 1 1 1 
5 yes 79 49 13 6 3 4 0 
6 yes 57 20 8 7 0 1 0 
7 yes 93 43 8 4 3 1 0 
8 no 39 17  
 
18% 
Declined NA NA NA NA 
9 yes 47 26 Declined NA NA NA NA 
10 yes 31 12 Declined NA NA NA NA 
11 no 35 15 Declined NA NA NA NA 
 
LEGEND 
HCT: hematopoietic stem cell transplantation; alloHCT: allogeneic hematopoietic stem cell 
transplantation; MD: medical doctor 
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Supplementary Table 2: List of Clinical Vignettes  
Vignette  Decription of the Clinical Vignette Diagnosis  Severity 
Scoring  
1 1. A female adult patient receives an allogeneic 
stem cell transplantation for a myelodysplasia. Her 
post transplantation period is uneventful, but 9 
months after transplantation she develops: 
• a red inflammatory rash on both arms, one month 
after discontinuation of immunosuppression.  
• There are no other abnormal signs or symptoms 
and her pulmonary function lab results are normal.  
• A biopsy of the skin of the forearm is suggestive 
for GVHD (likely GVHD - apoptosis in epidermal 
basal layer). 
Late acute GVHD Grade I 
2 A female adult patient receives an allogeneic stem 
cell transplantation for a chronic myeloid leukemia. 
Her pre-transplantation evaluation is unremarkable. 
Around day 90, she develops: 
• dyspnea when walking on flat ground.  
• A pulmonary evaluation reveals a newly 
decreased FEV1* of 65%, with a FEV1/VC ratio** 
of 0.65 and a RV*** of 110%.   
• Air trapping is present on high resolution CT scan 
of the lungs.  
• Infections of the respiratory tract are excluded by 
a normal bronchial aspirate evaluation and her 
cardiac function is normal.  
• Her clinical exam and laboratory results are 
perfectly normal except for xerostomia (dry mouth), 
without impact on her oral intake. 
Classic Chronic GVHD Moderate 
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3 Four months after receiving an allogeneic stem cell 
transplantation, a female adult patient presents with: 
• anorexia, daily vomiting and an unintentional 
weight loss of about 15% of her pre-transplantation 
weight.  
• There are no other abnormal signs or symptoms 
and her lab results and pulmonary function tests are 
normal.  
• A stomach biopsy confirms GVHD (likely GVHD 
- gastric pit apoptosis). 
Late acute GVHD Grade II 
4 Four weeks after receiving an allogeneic stem cell 
transplantation, a male adult patient presents with: 
• an itchy erythematous rash involving the head and 
neck, and anorexia with major diarrhea (10x/day, 
about 2000ml/day) but no abdominal pain.  
• A colonoscopy confirms GVHD by biopsy (likely 
GVHD - crypt apoptosis in the intestines) and 
excludes a concomitant infection or drug toxicity.  
• His lab results are normal except for a low 
albumin and slightly elevated creatinine.  
• His pulmonary function tests are normal. 
Classic acute GVHD Grade III 
5 A female adult patient, 6 months after her 
allogeneic stem cell transplantation, develops: 
• two patches of morphea-like lesions (patches of 
leather-like, shiny skin) on the lower back 
(diameter 5cm)  
• with an elevation of liver enzymes (ALT, AST, 
AP and GGT a little more than 3x the upper normal 
limit), without other potential confounding cause.  
• Her pulmonary function tests are normal.  
• She reports dyspareunia (painful intercourse) and 
a gynecological exam reveals vaginal adhesions and 
scarring. 
Overlap Chronic GVHD SEVERE  
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6 Two months after receiving an allogeneic stem cell 
transplantation, a male adult patient develops: 
• relatively frequent diarrhea episodes (4 times/ a 
day) accompanied with very severely painful 
abdominal cramps.  
• A colonoscopy confirms GVHD by biopsy (likely 
GVHD – apoptosis in enterocytes and destruction 
of crypt architecture) and excludes a concomitant 
infection / drug toxicity.  
• His body weight is unchanged.  
• Liver enzymes are slightly elevated (ALT, AST, 
AP and GGT slightly more than twice the upper 
normal limit) and bilirubin is 3.5 mg/dL, without 
argument for infection, drug toxicity or veno-
occlusive disease.  
• Except for fatigue, there are no other abnormal 
signs or symptoms and the rest of his lab results are 
normal.  
• His pulmonary function tests are normal. 
Classic acute GVHD Grade IV 
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7 A male adult patient receives an allogeneic stem 
cell transplantation. Ten months later, he feels fine 
but he reports: 
• frequent muscle cramps and has noticed that some 
movements have become more difficult : an 
increasing tightness in his lower back,  arms and 
legs is making it more difficult to his daily jog and 
pick up items on the ground.  
• On clinical exam, the extension of the arms and 
the flexion of the wrist are somewhat decreased and 
the ankles moderately swollen without 
inflammatory features.  
• No other clinical abnormalities are found than 
new lichen sclerosus-like changes (white patches of 
firm thickened/crinkled skin with a tendency to 
scar) that have appeared on the penis.  
• An electromyography is normal. His laboratory 
exams are normal, including muscle enzymes.  
• His pulmonary function tests are normal.  
Classic Chronic GVHD Moderate 
8 Three months after her transplantation, a female 
adult allogeneic transplantation recipient presents 
with: 
• two new painful ulcerations in the mouth. Oral 
exam reveals lichen planus like changes and 1.5cm 
wide ulcerations. Microbial examination for 
candida and herpes are negative.  
• Weight is stable but the patient no longer tolerates 
sparkling drinks. Oral intake is preserved. 
• The rest of her clinical exam, pulmonary function 
tests and lab results are unremarkable.  
Classic Chronic GVHD MILD 
9 A male adult patient, five months after receiving an 
allogeneic stem cell transplantation, develops: 
• a new maculopapular inflammatory red rash on 
the hands and feet.  
Overlap Chronic GVHD MILD 
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• He also notices that his nails have become brittle 
and his eyes are more sensitive than before.  
• The ophthalmologist confirms signs of 
keratoconjunctivitis sicca with a slit lamp 
examination. Shirmer’s test shows a 3mm tear 
production after 5 minutes.  
• His ocular problems are totally relieved by using 
artificial teardrops twice a day.  
• Further exams reveal normal pulmonary function 
tests, an unremarkable clinical exam (except for the 
rash and dystrophic nails).  
• He has normal laboratory results except for 
slightly elevated alkaline phosphatase (AP) which 
are a little over twice the upper normal limit (2x 
ULN). 
10 Twelve months after her allogeneic stem cell 
transplantation, a female adult patient develops: 
• difficulties with swallowing due to non-painful 
xerostomia (dry mouth) and the impression that 
food remains stuck when she swallows.  
• Her weight remains stable but she needs to chew 
abnormally long and drink along almost all of her 
solid food intakes.  
• A gastroscopy confirms the presence of a new 
stenosis of the upper esophagus, which is 
successfully dilated but no biopsies are taken.  
• Her other clinical, laboratory and pulmonary 
function test evaluations are normal, except for 
some superficial sclerosis bilaterally in the lower 
arms and legs. 
Classic Chronic GVHD SEVERE  
 
LEGEND 
* FEV1 = forced expiratory volume in one second 
**FEV1/VC =Tiffeneau index or forced expiratory volume in one second divided by vital capacity 
***RV= residual volume 
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Supplementary Table 3: Full Binary (Correct vs Incorrect) Results of Participants for 
Individual GvHD vignettes 
LEGEND 
* missing results were considered as being incorrect; v.s.: versus; Δ: difference between   
     
 
  
Supplementary Table 3: Full Binary (correct vs. incorrect) Results of Participants for Individual GvHD Vignettes
All participants "APP" group "NO APP" group All participants "APP" group "NO APP" group
n=77 n=37 n=40 n=77 n=37 n=40
correct  69 (89.6%) 33 (89.2%) 36 (90%)  - 0.8 % correct  62 (80.5%) 33 (89.2%) 29 (72.5%)  + 16.7 %
incorrect   8 (10.4%) 4 (10.8%) 4 (10%)  incorrect   15 (19.5%) 4 (10.8%) 11 (27.5%)  
correct  60 (77.9%) 37 (100%) 23 (57.5%)  + 42.5% correct  48 (62.3%) 37 (100%) 11 (27.5%)  + 72.5% 
incorrect   17 (22.1%) 0 (0%) 17 (42.5%)  incorrect   29 (37.7%) 0 (0%) 29 (72.5%)  
correct  72 (93.5%) 34 (91.9%) 38 (95%)  - 3.1% correct  62 (80.5%) 35 (94.6%) 27 (67.5%)  + 27.1%
incorrect   5 (6.5%) 3 (8.1%) 2 (5%)  incorrect   15 (19.5%) 2 (5.4%) 13 (32.5%)  
correct  75 (97.4%) 37 (100%) 38 (95%) + 5% correct  40 (51.9%) 33 (89.2%) 7 (17.5%) + 71.7%
incorrect   2 (2.6%) 0 (0%) 2 (5%)  incorrect   37 (48.1%) 4 (10.8%) 33 (82.5%)  
correct  64 (83.1%) 35 (94.6%) 29 (72.5%)  + 22.1% correct  39 (50.6%) 19 (51.3%) 20 (50%)  + 1.3%
incorrect   13 (16.9%) 2 (5.4%) 11 (27.5%)  incorrect   38 (49.4%) 18 (48.6%) 20 (50%)  
correct  68 (88.3%) 36 (97.3%) 32 (80%)  + 17.3% correct  42 (54.5%) 30 (81.1%) 12 (30%)  + 51.1%
incorrect   9 (11.7%) 1(2.7%) 8 (20%)  incorrect   35 (45.5%) 7 (18.9%) 28 (70%)  
correct  66 (85.7%) 35 (94.6%) 31 (77.5%)  + 17.1% correct  48 (62.3%) 32 (86.5%) 16 (40%) + 46.5%
incorrect   11 (14.3%) 2 (5.4%) 9 (22.5%)  incorrect   29 (37.7%) 5 (13.5%) 24 (60%)  
correct  72 (93.5%) 36 (97.3%) 36 (90%) + 7.3% correct  53 (68.8%) 29 (78.4%) 24 (60%) + 18.4%
incorrect   5 (6.5%) 1 (2.7%) 4 (10%)  incorrect   24 (31.2%) 8 (21.6%) 16 (40%)  
correct  72 (93.5%) 37 (100%) 35 (87.5%)  + 12.5% correct  41 (53.2%) 29 (78.4%) 12 (30%)  + 48.4%
incorrect   5 (6.5%) 0 (0%) 5(12.5%)  incorrect   36 (46.7%) 8 (21.6%) 28 (70%)  
correct  74 (96.1%) 37 (100%) 37 (92.5%) + 7.5% correct  40 (51.9%) 25 (67.6%) 15 (37.5%) + 30.1%
incorrect   3 (3.9%) 0 (0%) 3 (7.5%)  incorrect   37 (48.1%) 12 (32.4%) 25 (62.5%)  
 
LEGEND
* missing results were considered as being incorrect
v.s.: versus; Δ: difference between 
Δ "App" vs. "No App" (%) 
Correct Severity Scoring
Mild
Mild
Moderate
Vignette  
number
Gold Standard 
Diagnosis 
Participant Diagnosis*
Gold Standard Severity 
Scoring 
Participant Severity 
Scoring
Δ "App" vs. "No App" (%) 
Correct Diagnosis 
Grade I
Grade II
Grade III
Grade IV
5
10
Late acute GVHD
Late acute GVHD
Classic acute 
GVHD
Classic acute 
GVHD
Classic Chronic 
GVHD
3
4
6
8
9
1
2
7
Classic Chronic 
GVHD
Severe
Moderate
Severe
Overlap Chronic 
GVHD
Classic Chronic 
GVHD
Classic Chronic 
GVHD
Overlap Chronic 
GVHD
12 
Supplementary Table 4: Post-test User experience and Usability Data ("APP" group only) 
LEGEND 
IQR: inter quartile range; TAM: Technology Assessment Model; PSSUQ: Post-Study System Usability 
Questionnaire   
Supplementary Table 4: Post-test User Experience and Usability Data ("APP" group only)
Perceived Usefulness – TAM   median score
 (7= extremely likely; 1= extremely unlikely)
Using the “EBMT GVHD app” would… n
Enable me to accomplish tasks more quickly. 37 5 (IQR 2; range: 2-7)
Improve my job performance. 37 6 (IQR 1; range: 5-7)
Increase my productivity. 37 5 (IQR 1; range: 3-7)
Enhance my effectiveness on the job. 37 6 (IQR 1; range: 4-7)
Make it easier to do my job. 37 6 (IQR 1; range: 3-7)
I would find the “EBMT GVHD app” useful in my job. 37 6 (IQR 1; range: 4-7)
System Usability – PSSUQ  median score 
(1= Strongly agree  ; 7= Strongly disagree) n
1. Overall, I am satisfied with how easy it is to use this system. 36 2 (IQR 1; range 1-3)
2. It was simple to use this system. 36 2 (IQR 1; range 1-5)
3. I could effectively complete the tasks and scenarios using this system. 36 2 (IQR 1; range 1-4)
4. I was able to complete the tasks and scenarios quickly using this system 36 3 (IQR 1; range 1-6)
5. I was able to efficiently complete the tasks and scenarios quickly using this system. 36 2 (IQR 1; range 1-6)
6. I felt comfortable using this system. 36 2 (IQR 2; range 1-5)
7. It was easy to learn to use this system. 36 1.5 (IQR 1; range 1-5)
8. I believe I could become productive quickly using this system. 36 2 (IQR 1; range 1-5)
System use subscale score 2 (IQR 1; range 1-5)
9. The system gave error messages that clearly told me how to fix problems. 26 2.5 (IQR2; range 1-6)
10. Whenever I made a mistake using the system, I could recover easily and quickly. 34 2 (IQR 1; range 1-5)
11. The information provided with this system was clear. 36 2 (IQR 0; range 1-3)
12. It was easy to find the information I needed. 29 2 (IQR 0; range 1-5)
13. The information provided for the system was easy to understand. 35 2 (IQR: 0; range 1-2)
14. The information was effective in helping me complete the tasks and scenarios. 35 2 (IQR: 0; range 1-3)
15. The organization of information on the system screens was clear. 36 2 (IQR: 1; range 1-6)
Information quality subscale score 2 (IQR 1; range 1-3)
16. The interface (= items you use to interact with the system e.g. screen, mouse, keyboard,…) of this system 
was pleasant. 35 2 (IQR: 1; range 1-6)
17. I liked using the interface of this system. 35 2 (IQR: 1; range 1-5)
18. This system has all the functions and capabilities I expect it to have. 36 2 (IQR: 1; range 1-3)
Interface quality subscale score 2 (IQR 1; range 1-3)
19. Overall, I am satisfied with this system. 36 2 (IQR: 1; range 1-3)
Overall PSSUQ (items 1-19) 2 (IQR 0,4; range 1-3)
Predicted use
Reported level of likelihood of using the app in the future (Likert scale 1 (lowest)-10 (highest)) 36 8 (IQR 3; range: 1-10)
Actual use
Reported level of comfort using the app  in English (Likert scale 1 (lowest)-10 (highest)) 37 9 (IQR 2.5; range: 3-10)
LEGEND
IQR: inter quartile range; TAM: Technology Assessment Model; PSSUQ: Post-Study System Usability Questionnaire  
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Supplemental Figures 
Supplementary  Figure 1 – The superiority of the eGVHD App  in GvHD assessment is similar regardless 
of center effect for diagnosis (A) and severity scoring (B) 
Supplementary  Figure 2 – The superiority of the eGVHD App  in GvHD assessment is similar regardless 
of professional background for diagnosis (A) and severity scoring (B) 
Supplementary  Figure 3 – The superiority of the eGVHD App  in GvHD assessment is similar regardless 
of the age category of the user for diagnosis (A) and severity scoring (B) 
Supplementary  Figure 4 – The superiority of the eGVHD App  in GvHD assessment is similar regardless 
of the user self-reported experience with GvHD assessment for diagnosis (A) and severity scoring (B) 
Legend supplementary Figure 4: 
User experience with GvHD assessment was categorized according to the number of HCT patients the 
health care professionals reported to evaluate per week: “very low” experience (less than one HCT patient 
per week),  “low” (1 to 6 weekly contacts with HCT patients), “moderate” experience (7 to 15 weekly 
contacts with HCT patients); “high” experience (more than 15 weekly contacts with HCT patients) 
Supplementary  Figure 5 – The superiority of the eGVHD App  in GvHD assessment is similar regardless 
of the user self-reported comfort with GvHD assessment guidelines for diagnosis (A) and severity 
scoring (B) 
Legend supplementary Figure 5: 
User self-reported comfort with GvHD assessment guidelines was categorized based on the pre-test survey 
question “How comfortable are you with using the above mentioned criteria in your daily practice on a 
Likert scale of 1-10 (1= Not at all comfortable; 10= extremely comfortable)”: “low” comfort (response 4 
or less),  “moderate” comfort (response between 5 and 7), “high” comfort (response 8 or above). 
A. GvHD Diagnosis B. GvHD Severity Scoring
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